Genelux (GNLX) Competitors

$3.19 +0.22 (+7.41%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$3.28 +0.10 (+2.98%)

As of 07:16 AM Eastern

GNLX vs. UPB, STTK, ZURA, LYEL, and ADCT

Should you buy Genelux stock or one of its competitors? MarketBeat compares Genelux with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genelux include Upstream Bio (UPB), Shattuck Labs (STTK), Zura Bio (ZURA), Lyell Immunopharma (LYEL), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

How does Genelux compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Upstream Bio presently has a consensus target price of $39.00, suggesting a potential upside of 316.67%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 464.26%. Given Genelux's higher possible upside, analysts clearly believe Genelux is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

37.3% of Genelux shares are held by institutional investors. 13.6% of Upstream Bio shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to Upstream Bio's net margin of -5,026.03%. Upstream Bio's return on equity of -36.48% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-5,026.03%	-36.48%	-35.38%
Genelux	N/A	-174.55%	-123.65%

Upstream Bio has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Genelux has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

In the previous week, Genelux had 18 more articles in the media than Upstream Bio. MarketBeat recorded 22 mentions for Genelux and 4 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Genelux's score of -0.06 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genelux has lower revenue, but higher earnings than Upstream Bio. Genelux is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	178.73	-$143.44M	-$2.67	N/A
Genelux	$10K	14,303.96	-$32.15M	-$0.85	N/A

Summary

Upstream Bio beats Genelux on 9 of the 17 factors compared between the two stocks.

How does Genelux compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Shattuck Labs has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Shattuck Labs currently has a consensus price target of $13.00, indicating a potential upside of 92.59%. Genelux has a consensus price target of $18.00, indicating a potential upside of 464.26%. Given Genelux's higher possible upside, analysts clearly believe Genelux is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Shattuck Labs' return on equity of -60.73% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Genelux	N/A	-174.55%	-123.65%

Genelux has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	517.59	-$48.81M	-$0.63	N/A
Genelux	$10K	14,303.96	-$32.15M	-$0.85	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Genelux had 17 more articles in the media than Shattuck Labs. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.04 beat Genelux's score of -0.06 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Shattuck Labs beats Genelux on 10 of the 15 factors compared between the two stocks.

How does Genelux compare to Zura Bio?

Genelux (NASDAQ:GNLX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Genelux has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Genelux had 17 more articles in the media than Zura Bio. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.16 beat Genelux's score of -0.06 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.3% of Genelux shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zura Bio's return on equity of -55.74% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Zura Bio	N/A	-55.74%	-48.07%

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 464.26%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 123.96%. Given Genelux's higher probable upside, research analysts plainly believe Genelux is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Genelux has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	14,303.96	-$32.15M	-$0.85	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Summary

Genelux and Zura Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Genelux compare to Lyell Immunopharma?

Genelux (NASDAQ:GNLX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

In the previous week, Genelux had 16 more articles in the media than Lyell Immunopharma. MarketBeat recorded 22 mentions for Genelux and 6 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.41 beat Genelux's score of -0.06 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.3% of Genelux shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 464.26%. Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 123.49%. Given Genelux's higher possible upside, equities analysts clearly believe Genelux is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lyell Immunopharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Genelux has higher earnings, but lower revenue than Lyell Immunopharma. Genelux is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	14,303.96	-$32.15M	-$0.85	N/A
Lyell Immunopharma	$40K	11,221.73	-$274.45M	-$13.80	N/A

Summary

Genelux beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

How does Genelux compare to ADC Therapeutics?

Genelux (NASDAQ:GNLX) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market.

Genelux has higher earnings, but lower revenue than ADC Therapeutics. Genelux is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	14,303.96	-$32.15M	-$0.85	N/A
ADC Therapeutics	$81.36M	5.43	-$142.62M	-$1.05	N/A

In the previous week, Genelux had 22 more articles in the media than ADC Therapeutics. MarketBeat recorded 22 mentions for Genelux and 0 mentions for ADC Therapeutics. Genelux's average media sentiment score of -0.06 beat ADC Therapeutics' score of -0.49 indicating that Genelux is being referred to more favorably in the media.

Company	Overall Sentiment
Genelux	Neutral
ADC Therapeutics	Neutral

37.3% of Genelux shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
ADC Therapeutics	-173.02%	N/A	-44.70%

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 464.26%. ADC Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 130.15%. Given Genelux's higher possible upside, equities analysts clearly believe Genelux is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genelux beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$133.18M	$3.42B	$6.30B	$12.28B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-3.75	18.67	21.03	25.58
Price / Sales	14,303.96	305.47	554.66	78.88
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	6.25	6.75	9.78	6.66
Net Income	-$32.15M	$24.11M	$3.55B	$333.63M
7 Day Performance	12.72%	-0.53%	-0.52%	-0.12%
1 Month Performance	20.83%	0.34%	1.21%	3.93%
1 Year Performance	32.92%	78.62%	41.26%	36.07%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	2.0384 of 5 stars	$3.19 +7.4%	$18.00 +464.3%	+28.6%	$133.18M	$10K	N/A	10	Trending News Earnings Report Analyst Revision
UPB Upstream Bio	2.4065 of 5 stars	$9.12 -2.0%	$39.00 +327.6%	+8.2%	$496.31M	$2.85M	N/A	38	News Coverage Positive News Earnings Report
STTK Shattuck Labs	3.3898 of 5 stars	$6.54 -5.5%	$12.50 +91.1%	+602.7%	$494.31M	$1M	N/A	100	Positive News Earnings Report
ZURA Zura Bio	2.8799 of 5 stars	$5.18 -2.6%	$10.75 +107.5%	+296.7%	$491.48M	N/A	N/A	3	Earnings Report
LYEL Lyell Immunopharma	2.1043 of 5 stars	$20.62 -0.5%	$43.00 +108.5%	+137.8%	$481.07M	$40K	N/A	270	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. UPB, STTK, ZURA, LYEL, and ADCT

How does Genelux compare to Upstream Bio?

Summary

How does Genelux compare to Shattuck Labs?

Summary

How does Genelux compare to Zura Bio?

Summary

How does Genelux compare to Lyell Immunopharma?

Summary

How does Genelux compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. UPB, STTK, ZURA, LYEL, and ADCT

How does Genelux compare to Upstream Bio?

Do analysts rate UPB or GNLX?

Do institutionals and insiders have more ownership in UPB or GNLX?

Is UPB or GNLX more profitable?

Which has more risk and volatility, UPB or GNLX?

Does the media refer more to UPB or GNLX?

Which has better valuation and earnings, UPB or GNLX?

Summary

How does Genelux compare to Shattuck Labs?

Which has more volatility & risk, STTK or GNLX?

Do analysts prefer STTK or GNLX?

Is STTK or GNLX more profitable?

Which has better earnings & valuation, STTK or GNLX?

Do insiders & institutionals have more ownership in STTK or GNLX?

Does the media refer more to STTK or GNLX?

Summary

How does Genelux compare to Zura Bio?

Which has more volatility & risk, GNLX or ZURA?

Does the media prefer GNLX or ZURA?

Do institutionals & insiders hold more shares of GNLX or ZURA?

Is GNLX or ZURA more profitable?

Do analysts rate GNLX or ZURA?

Which has stronger valuation & earnings, GNLX or ZURA?

Summary

How does Genelux compare to Lyell Immunopharma?

Which has more risk & volatility, GNLX or LYEL?

Does the media prefer GNLX or LYEL?

Do insiders and institutionals hold more shares of GNLX or LYEL?

Is GNLX or LYEL more profitable?

Do analysts recommend GNLX or LYEL?

Which has preferable valuation and earnings, GNLX or LYEL?

Summary

How does Genelux compare to ADC Therapeutics?

Which has more risk & volatility, GNLX or ADCT?

Which has preferable valuation and earnings, GNLX or ADCT?

Does the media prefer GNLX or ADCT?

Do insiders and institutionals hold more shares of GNLX or ADCT?

Is GNLX or ADCT more profitable?

Do analysts recommend GNLX or ADCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools